Artificial Intelligence Achieves Near-Human Performance in Image Analysis
|
By LabMedica International staff writers Posted on 27 Jun 2016 |

Image: A micrograph showing a lymph node invaded by ductal breast carcinoma, with extension of the tumor beyond the lymph node. H&E stain. The dark purple (center) is lymphocytes (part of a normal lymph node). Surrounding the lymphocytes and extending into the surrounding fat (top of image) is ductal breast carcinoma (Photo courtesy of Michael Bonert / Wikimedia).
A research team has developed an artificial intelligence (AI) method that trains computers to interpret pathology images. In a recent test of the method developed to examine images of lymph nodes, human complemented with computer analyses together identified breast cancer with 99.5% accuracy.
The method was put to the test in a “challenge” competition held at the 2016 annual meeting of the International Symposium of Biomedical Imaging (ISBI; April 2016, Prague, Czech Republic). “Identifying the presence or absence of metastatic cancer in a patient’s lymph nodes is a routine and critically important task for pathologists,” said team leader Prof. Andrew Beck, MD, PhD, pathologist, Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA) and Harvard Medical School (HMS; Boston, MA, USA), “Peering into the microscope to sift through millions of normal cells to identify just a few malignant cells can prove extremely laborious using conventional methods. We thought this was a task that the computer could be quite good at – and that proved to be the case.”
“Our AI method is based on deep learning, a machine-learning algorithm used for a range of applications including speech recognition and image recognition,” explained Prof. Beck, “This approach teaches machines to interpret the complex patterns and structure observed in real-life data by building multi-layer artificial neural networks, in a process which is thought to show similarities with the learning process that occurs in layers of neurons in the brain’s neocortex, the region where thinking occurs.”
In an objective evaluation in which researchers were given slides of lymph node cells and asked to determine whether or not they contained cancer, the team’s automated diagnostic method was accurate approximately 92% of the time. “This nearly matched the success rate of a human pathologist, whose results were 96% accurate,” said Aditya Khosla of MIT, who with Prof. Beck recently formed a start-up company, PathAI, to further develop AI technology for pathology.
“The truly exciting thing was when we combined the pathologist’s analysis with our automated computational diagnostic method, the result improved to 99.5% accuracy,” said Prof. Beck, “Combining these two methods yielded a major reduction in errors.”
The team trained the computer to distinguish between cancerous tumor regions and normal regions based on a deep multilayer convolutional network. “In our approach, we started with hundreds of training slides for which a pathologist has labeled regions of cancer and regions of normal cells,” said Dayong Wang, PhD, “We then extracted millions of these small training examples and used deep learning to build a computational model to classify them.” They then identified the specific training examples for which the computer is prone to making mistakes and re-trained the computer using greater numbers of the more difficult training examples. In this way, the computer’s performance continued to improve.
Only recently “improved scanning, storage, processing, and algorithms have made it possible to pursue this mission effectively. Our results in the ISBI competition show that what the computer is doing is genuinely intelligent and that the combination of human and computer interpretations will result in more precise and more clinically valuable diagnoses to guide treatment decisions,” said Prof. Beck.
Jeroen van der Laak, PhD, who leads a digital pathology research group at Radboud University Medical Center in the Netherlands and was an organizer for the competition, said, “When we started this challenge, we expected some interesting results. The fact that computers had almost comparable performance to humans is way beyond what I had anticipated. It is a clear indication that AI is going to shape the way we deal with histopathological images in the years to come.”
The team described their method in a technical report posted June 2016 in the arXiv.org repository.
Related Links:
Beth Israel Deaconess Medical Center
Harvard Medical School
The method was put to the test in a “challenge” competition held at the 2016 annual meeting of the International Symposium of Biomedical Imaging (ISBI; April 2016, Prague, Czech Republic). “Identifying the presence or absence of metastatic cancer in a patient’s lymph nodes is a routine and critically important task for pathologists,” said team leader Prof. Andrew Beck, MD, PhD, pathologist, Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA) and Harvard Medical School (HMS; Boston, MA, USA), “Peering into the microscope to sift through millions of normal cells to identify just a few malignant cells can prove extremely laborious using conventional methods. We thought this was a task that the computer could be quite good at – and that proved to be the case.”
“Our AI method is based on deep learning, a machine-learning algorithm used for a range of applications including speech recognition and image recognition,” explained Prof. Beck, “This approach teaches machines to interpret the complex patterns and structure observed in real-life data by building multi-layer artificial neural networks, in a process which is thought to show similarities with the learning process that occurs in layers of neurons in the brain’s neocortex, the region where thinking occurs.”
In an objective evaluation in which researchers were given slides of lymph node cells and asked to determine whether or not they contained cancer, the team’s automated diagnostic method was accurate approximately 92% of the time. “This nearly matched the success rate of a human pathologist, whose results were 96% accurate,” said Aditya Khosla of MIT, who with Prof. Beck recently formed a start-up company, PathAI, to further develop AI technology for pathology.
“The truly exciting thing was when we combined the pathologist’s analysis with our automated computational diagnostic method, the result improved to 99.5% accuracy,” said Prof. Beck, “Combining these two methods yielded a major reduction in errors.”
The team trained the computer to distinguish between cancerous tumor regions and normal regions based on a deep multilayer convolutional network. “In our approach, we started with hundreds of training slides for which a pathologist has labeled regions of cancer and regions of normal cells,” said Dayong Wang, PhD, “We then extracted millions of these small training examples and used deep learning to build a computational model to classify them.” They then identified the specific training examples for which the computer is prone to making mistakes and re-trained the computer using greater numbers of the more difficult training examples. In this way, the computer’s performance continued to improve.
Only recently “improved scanning, storage, processing, and algorithms have made it possible to pursue this mission effectively. Our results in the ISBI competition show that what the computer is doing is genuinely intelligent and that the combination of human and computer interpretations will result in more precise and more clinically valuable diagnoses to guide treatment decisions,” said Prof. Beck.
Jeroen van der Laak, PhD, who leads a digital pathology research group at Radboud University Medical Center in the Netherlands and was an organizer for the competition, said, “When we started this challenge, we expected some interesting results. The fact that computers had almost comparable performance to humans is way beyond what I had anticipated. It is a clear indication that AI is going to shape the way we deal with histopathological images in the years to come.”
The team described their method in a technical report posted June 2016 in the arXiv.org repository.
Related Links:
Beth Israel Deaconess Medical Center
Harvard Medical School
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







